Shared insight on recent advances in KRAS-mutant NSCLC, with a focus on new therapies on the horizon.
EP. 1: Evolution of Targeted Therapy in Advanced NSCLC
Watch
EP. 2: Targeted Therapy in NSCLC: Improvements in Molecular Testing
EP. 3: History of KRAS Testing in Advanced NSCLC
EP. 4: An Overview of KRAS Tumor Biology
EP. 5: KRAS Mutation Subtypes in Advanced NSCLC
EP. 6: Advanced NSCLC: Rationale Behind KRAS Inhibition
EP. 7: KRAS-Mutant NSCLC: Current Systemic Treatment Options
EP. 8: Impact of Coalterations on KRAS-Mutant NSCLC
EP. 9: KRAS G12C Inhibition in Advanced NSCLC: AMG 510
EP. 10: Practical Considerations for AMG 510 in KRAS-Mutant NSCLC
EP. 11: KRAS G12C Inhibition in Advanced NSCLC: MRTX849
EP. 12: KRAS G12C Inhibitors: Acquired Resistance and Combo Strategies
EP. 13: Future Directions in Managing KRAS-Mutant Advanced NSCLC
